The implant is engineered to offer PER-001’s sustained release, aiming for a “convenient” dosing frequency of every six ...
dexamethasone IVT implant for the treatment of RVO, noninfectious uveitis affecting the posterior segment, and DME; (4) aflibercept for the treatment of AMD, RVO, and DME; (5) ocriplasmin for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback